Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2002

View Archived Issues

Little or no activity for KW-2189 in advanced malignant melanoma

CpG oligodeoxynucleotides may be useful against prion infection

Measurement of BNP levels provides accurate diagnosis of CHF

Fuzeon (T-20) set for launch in 2003

FDA approval for NMP22 BladderChek test

NuGEN Technologies awarded SBIR grant for anthrax test

Lescol sNDA filed for secondary prevention of cardiovascular events in angioplasty patients

FDA approves pediatric labeling of Prevacid

Bruno to market Avanir's docosanol 10% cream in Italy

HE-2200 cleared to enter phase II in patients with elevated cholesterol

Inspire and Discovery collaborate on P2Y12 antagonist program for cardiovascular disease

Pivotal phase III trial of RSR-13 completes enrollment

Approvable letter for lercanidipine

Exelixis and Bristol-Myers Squibb extend drug discovery collaboration

AstraZeneca to provide additional information for Crestor approval

Serono and Genentech sign marketing agreement for Raptiva, formerly Xanelim

Maxim updates Ceplene third quarter progress

Novel GSK-3 inhibitors and their use in diabetes, neurodegeneration, etc.

New antiemetic compound prepared and tested at UCB

Bayer presents new PDE2 inhibitors with utility in dementia

Novel iNOS inhibitor prepared by GSK researchers

Novel HDAC inhibitors identified at Beacon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...